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Introduction
Systemic Lupus Erythematosus (SLE) is a systemic 
autoimmune disease with incidence of 6-35 cases per 
100,000 people in year and appears mainly in fertility 
age of women (Draborg et al., 2012). Disease signs are 
butterfly rush in face, discoid rush, sensitivity to light, 
mouth ulcer, arthritis, serositis, renal involvement, 
blood disorder (anemia, leukopenia, lymphocytopenia, 
thrombocytopenia) and neuropathy and positive tests anti-
nuclear antibody(ANA) and anti dsDNA antibody (Fauci 
& Morens, 2012). Ethology of lupus is multifactorial and 
influenced by genetic and peripheral factors including sex, 
age and social-economic situation.
Typical revolution of disease is seen as alternative 
periods of exacerbation and remission. Environmental 
risk factors for SLE are including UV lights, drugs, 
special chemistry substances and infections specially 
EBV (Draborg et al., 2012; Fauci et al., 2012). EBV is 
known as human herpes type 4 (HHV-4) that is linear 
double stranded DNA virus with capsid and envelope. 
EBV virus is an infectious agent over the world and is 
approximately latent in 95% of population. Virus transmits 
from saliva and become transcribed in mucosal surfaces 
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of oropharynx and nasopharynx specially in tonsils region 
and then enters to underlying tissue and make infection by 
binding of its envelope glycoprotein to special receptor 
on B lymphocyte. This virus has ability to shifting from 
lytic cycle to latency (Draborg et al., 2012).
Infection with this virus is asymptomatic in childhood 
but in adolescence causes infectious mononucleosis with 
symptoms of skin rush, palatal exanthema, arthralgia, 
renal disorder and anemia (Straus et al., 1993). During the 
lytic cycle, DNA of virus is transcribed and strengthen of 
expressed genes reached to 100-1000 times. This events 
causes the pouring virus to saliva which can infect other 
B lymphocytes and epithelial cells. Virus enters become 
latent in response to host immunity. Progress of infection 
in B lymphocytes during lytic cycle can be controlled 
specifically by T cytotoxic cells which declines infected B 
lymphocytes and induces the latent phase (Draborg et al., 
2012). EBV stimulates the proliferation of B lymphocytes 
after infection and EBV become long standing in SLE 
patients with genetically susceptibility. On the other 
hand B lymphocytes infected with virus are a continual 
source for producing auto antigen and auto antibody; also 
some of protein sequences of virus have homology with 
human auto antigens. The reaction of antinuclear 1, 2 
1Autoimmune Diseases Research Center, 2Anatomical Sciences Research Center, Kashan University of Medical Sciences, Kashan, 
Iran. *For Correspondence: batol_zamani2007@yahoo.com
Ahmad Piroozmand et al
Asian Pacific Journal of Cancer Prevention, Vol 18524
autoantibody created against virus interacts with human 
auto antigen and produces SLE disease (Amaral et al., 
2014; Namjou et al., 2007).
High titer of anti EBV antibody and serum appearance 
of virus in persons with SLE in compare with control 
people was seen. Antibody response in serum lonely 
cannot show the presence of virus directly, but other 
methods like as PCR on saliva or peripheral blood samples 
will be helping to show the presence and activity of virus 
(Draborg et al., 2012).
PCR product was quantified through real-time PCR 
using a fluorogenic probe. Nowadays this method is 
become a suitable alternative for other quantitative 
PCR methods and it is used extensively in the world for 
measuring load of EBV virus. Lupus patients have the 
infected B lymphocytes at least 10 times more than normal 
people and this increase can be correlated to increase in 
activity of disease (Gross et al., 2005).
In one study by using this method, 40 times increasing 
of EBV virus load in SLE patients compared to normal 
people was reported (Kang et al., 2004). In one another 
study it was shown a significant increase in serum level of 
EBV DNA in 42% of SLE patients compared with 3% of 
controls (Lu et al., 2007). Moon and Colleagues in 2004 
showed the prevalence and type of infection with EBV 
was equal in people with SLE and controls (94-98.5%), 
but viral load in peripheral blood mononuclear cells of 
persons with SLE was 15 times of control people (Moon 
et al., 2004).
Recently there are reports that some people after 
affecting of infectious mononucleosis had acquired lupus 
erythematous which is documentation for the theory of 
lupus caused by EBV. It was seen in normal people that 
out of 100,000 to 1000,000 B lymphocytes, one cell is 
latently infected by EBV, but in people with SLE the 
number of infected cell is higher and every cell contains 
30 viral episome (Ito et al., 2016; Macsween et al., 2014; 
Rocchi et al.,1977). 
Katz and Colleagues studied on 13 SLE patients using 
PCR method and they did not find any viral genome in 
peripheral blood mononuclear cells; that is maybe because 
of problem(s) in type of used PCR method (Katz et al., 
2001).
With respect to slight studies in the case of viral serum 
load in SLE patients, we tried to study about load of this 
virus in SLE patients and inactive status of disease using 
real-time PCR method in order to understanding the role of 
EBV virus in create and activity enhancement of disease, 
through the understanding of this role we can prevent SLE 
disease and it’s activity in future. 
Materials and methods
In this Cross-sectional study 40 SLE patients referred 
to rheumatology clinic of Beheshti Hospital and diagnosed 
as based on American rheumatology Association (ACR) 
criteria and included in study according to the purpose 
and as a census were selected during the year of 2014.
Activity of disease was measured by SLEADI standard 
questionnaire (Lotfi et al., 2016; Saba et al., 2017; Sharif 
et al., 2016). This questionnaire Contains some clinical 
and laboratory findings related to SLE disease (Fauci and 
Morens, 2012). In the base of questionnaire, score less 
than 6, disease is inactive form and score equal or more 
than 6 until 12 reveals the mild to moderate active form 
and score more than 12 consider as severe active form.
After obtaining the informed consent from all patients 
and giving sufficient explanation for them regarding to 
security of information, 10 mL vein blood sample was 
taken and was sent to PCR center of Kashan Beheshti 
Hospital (Ferdosian et al., 2015; Jalali et al., 2016; Kashani 
et al., 2015). In order to assess the serum viral load of 
EBV, first buffy coat DNA was extracted by High Pure 
Viral Nucleic Acid Kit (Roche, kit Mannheim, Germany) 
and was kept in -20ºC freezer. For measuring viral load 
, extracted DNA along with other substances included in 
Master mix and primer /probe from BKRF1 gen region 
(table1) and applied Bio-system real time PCR (Taq-Man 
PCR method) was used. 
In summary 250 ng of DNA extracted from 5 ml buffy coat 
added to PCR master mix containing;10mMTris(PH:8.3), 
KCl(50mM), EDTA(10mM), MgCl2(5mM),100mM 
of dATP, dCTP, dGTP and dTTP, primers(0.2mM each 
one), 0.1 mM Taq Man, Enzyme (Applied Biosystems). 
Following activation of Ampli-Taq gold Enzyme for 10 
min in 95ºC, 45-50 cycles including 15 sec in 95ºC, 1 min 
in 62ºC for PCR protocol was considered. Mean of EBV 
virus load is obtained in 2 groups with active and inactive 
disease and was recorded as copy/ml. 
Statistical method
In this study we applied one way, but 2-tailed 
independent samples Student’s t tests. These analyses were 
done using analysis of variance (ANOVA) (Hosseini et al., 
2016; Kashani et al., 2012; Nikzad et al., 2013). P-values 
<0.05 were considered statistically significant. The test 
compared the average of two independent groups with 
each other. In this test, the average obtained from a random 
sample, are judged. This means that the samples from 
two different groups, whether equal or unequal number 
of samples are randomly selected and the average of the 
two groups were compared. The Kolmogrov-Smirnov 
test was applied to determine the normal distribution of 
variables (Dehghani et al., 2016a; Dehghani et al., 2016b; 
Kashani et al., 2013). All statistical analyses were done 
using the Statistical Package for Social Science version 
19 (SPSS Inc., Chicago, Illinois, USA) (Dehghani et al., 
2016c; Kashani et al., 2013).
Results
In the present study, that is done on 40 SLE patients, 
there was 37(92.5%) women and 3 (7.5%) men that 
abundance ratio of women to men was 9 to 1. The duration 
of the disease was in 27 person (67.5%) less than 5 years, 
in 12 person (30%) between 5-10 years and in 1 person 
(2.5%) higher than 10 years. EBV DNA was negative in 
13 person (32.5%) and positive in 27 person (67.5%). In 
active form of lupus, the amount of negative and positive 
DNA test was 15% and 85% respectively, but in inactive 
form was 50% in each group (Table 1). On the other hand 
most people with positive DNA test (63%) had active form 
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39 woman and 5 man had SLE, most of men and women 
had active lupus.
The results of present study showed 67.5% of SLE 
patients had positive EBV and 32.5% were negative. In 
active form the percentage of negative and positive EBV 
test was 15% and 85% respectively. In inactive form was 
50% and 50%. The most of patients with positive EBV 
test (63%) had active form of disease, whereas the most of 
people with negative EBV test (76.9%) had inactive form, 
these differences were statistically significant. 
Lu et al., (2007) in study on 93 SLE patients showed 
32.1% of them were positive EBV test and in control 
group had 4.1% positive test and also in this study it was 
found that prevalence of EBV in patients with active form 
is more than inactive form , similar to the results in our 
study. In another study on 33 Egyptian patients with Lupus 
and 30 healthy person, 32 (96.9%) were positive EBV test 
and in control group 20 people (66.6%) had positive test 
(Mohamed, Hasen, Mohammed and Elmaraghy, 2015).
The results of the studies carried out by others is 
different from the present study, which can be the cause 
of this difference in laboratory methods to be used, so that 
in some of these studies only of serum antibodies against 
the virus is used. That is not an accurate test and it shows 
a higher rate of being positive, while in present study we 
used Real-Time PCR which is more accurate. Average of 
EBV viral load in patients with active and inactive lupus 
was 6,798 copy/ml and 28.25copy/ml respectively, that 
this difference is statistically considerable. on the other 
hand, the average of EBV viral load in women with active 
form was 5803.3 copy/mol and in women with inactive 
form was 29.73copy/ml, that showed the average virus 
load in women in active form is more than inactive that 
these differences was statistically significant. In a study 
by Gross in order to check EBV viral load in patients 
with systemic lupus, it was shown that viral load of 
EBV in patients compared to the healthy group has been 
significantly higher, so that comparison of average viral 
load in two group has showed viral load in lupus patients 
is about 40 times more than control group. In this study it 
was found that average viral load in patients with active 
& most people with negative DNA test (76.9) had inactive 
form of SLE disease (P-value < 0.01). 
In terms of the severity of disease activity, 17.5 
% of patients had mild and moderate activity, whilst 
32.5% of them had severe activity. The average EBV 
load in active and inactive was 6,798 copy/ml and 28.2 
copy/ml respectively; this difference was statistically 
significant (P-value =0.003). The average load of virus 
in women with active form was more than inactive form, 
5803.3copy/ml and 29.73copy/ml respectively; that was 
statistically significant (P-value =0.003) (Table 2).
Discussion 
The results of this study showed that the 7.5% of SLE 
patients were men and 92.5% were women. In different 
forms of lupus, the proportion of women is more than 
men which in text books, this ratio of male to female 
involvement is 9-10 to 1 respectively. The majority of 
women (51 %) had an inactive form and the majority 
of men (66.7%) had the active form of Lupus, but these 
differences, weren’t statistically significant. In a study on 
76 patients with inactive lupus and 42 patients with active 
lupus it was showed that in both patients with active and 
inactive lupus, number of women was more than men 
(Larsen et al., 2011). 
In another study 24 out of 27 SLE patients with 
positive EBV were women and 3 out of 27 were men. 
Among patients with Lupus and negative EBV test , 
68 and 14 patients were women and men respectively 
(Ulff-Møller et al., 2010). Also other study on 120 lupus 
patients it showed 129 out of them were women and 85% 
of women had active lupus (Shoenfeld et al., 2009). In 
a study that conducted by Chen et al., (2005) in Taiwan 
on 36 patients, there was 34 woman and only 2 man, and 
most of active lupus patients were women. Moreover other 
research on 82 out of 96 SLE patients were woman (94% 
of them with active SLE) and the rest were men; most of 
them had inactive Lupus. These findings are contrary to 
the findings of our study (D.Y. Chen et al., 2010). Study 
of Tazi et al., (2009) in 44 SLE patients, revealed that 
Table 1. Primers and Probes Used for EBV Viral Load Assessment
Viral gene Sequence (5'–3') Primer/probe
BKRF1 CGG TGT GTT CGT ATA TGG AGG TAG TA Forward
BKRF1 AGA CCA TGA AAT AAC AGA CAA TGG AC Reverse
BKRF1* AGT CGT CTC CCC TTT GGA ATG GC 3'-Fluorescein probe
Star arrow*, 3'-Fluorescein probe
SLE disease N Mean SD P-value*
Active 18 5803.3 7178.0 0.003
Inactive 19 29.7 43.3
EBV Positive Active 17 7997.6 9003.5 0.002
Inactive 10 56.5 45.5
Severity Mild to moderate 7 6608.6 7769.1 0.946
Severe 13 6900.0 9563.7
Table 2. The Average and Standard Error of EBV Viral Load with SLE Disease/ EBV Positive iIn Form of Active or 
Inactive of Disease and Patients with Active Lupus in Term of Severity of Disease
*Statistical significance was attained when (P-Value < 0.05).
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lupus is more than inactive ones and there was statistically 
significant difference. And also it was shown that the viral 
load has a direct relationship with the severity of disease 
activity (Gross et al., 2005). Kang in 2004 by studying on 
32 lupus patients in New York USA , showed that increase 
in viral load in patients with Lupus is 40 times more than 
healthy group and this factor in patients with active lupus 
EBV virus load is more than patients with inactive lupus 
(Kang et al., 2004).
In a study Larsen on 76 patients affected by inactive 
lupus and 42 patients with active lupus showed that 
average of viral load in patients with active and inactive 
lupus is 19,300copy/ml (35,400-2,800) and 17300copy/ml 
(28,900-2,900) respectively. This difference is statistically 
significant and its results is similar to our results, but in 
this study amount of viral load in patients with inactive 
lupus is higher than that in our study (Larsen et al., 2011). 
Present study showed that the amount of EBV viral load in 
patients with mild to moderate active lupus and severe was 
6608 copy/mol and 7769 copy/ml respectively that this 
difference was not statistically significant. In a research 
on 33 Egyptian lupus patients and 30 healthy controls, the 
frequency of virus in patients with higher severity was 
more (Mohamed et al., 2015). The results of this study 
was different from our study results.
In a study by Moon on 24 lupus patients and 29 healthy 
controls showed EBV viral load in patients with active 
lupus was higher than inactive lupus and also the amount 
of viral load in patients with mild active lupus compared to 
patient with severe active lupus is significantly different. 
The difference is approximately 5 times the estimated 
and this is different from the results of the present study 
(Moon et al., 2004).
In another study on 24 lupus patients and 44 healthy 
controls showed that average viral load and Antibody 
against EBV virus in lupus patients was higher than 
control group and in patients with more severe lupus, 
average viral load is 3 times more than patients with mild 
lupus that this difference was statistically significant. 
These results are different from the results of our study. 
The differences in the studies could be due to the use of 
different methods and devices with different precision 
or perhaps due to the conditions of the society and the 
society of our sample (Tazi et al., 2009).
The results of present study showed the average viral 
load in patients with diploma or lower education level 
in active and inactive form was 10,138copy/ml and18.1 
copy/ml respectively and in patients with persons with 
education level higher than diploma was 4,517.7copy/ml 
and 36.5 copy/mol respectively, that this difference was 
statistically meaningful. It also was shown in the present 
study that the viral load in patients with intermediate 
economic situation in active and inactive form was 
7,113copy/ml and 28.2 copy/ml respectively. This result 
was statistically significant; Of course these variables in 
other studies have not yet been reviewed. At the current 
study due to the low number of men in we did statistical 
analysis on women only.
According to this study the amount of infection with 
EBV virus in SLE patients is high and in viral load of 
virus in patients with active lupus is higher than patients 
with inactive lupus; this is evidence for the role of virus 
on activity and pathogenesis of disease.
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